• Low risk business model in emerging life sciences with growth prospects.
  • Nine of the eleven products in the company?s portfolio are already registered in the US, EU, or both
  • On our conservative projections Sinclair Pharma should become profitable in 2007.
  • Our fair value estimate of 165p compares with the current share price of 107.5p

Unlock this Article with a 14 day free trial

or Unlock with your email

Already have an account?
Login here